Immutep S.A.S.

11 clinical trials · Sponsor

Record	Firm	Date
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) (NCT06726265)	Immutep S.A.S.	2025-03-21
A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy Volunteers (NCT06637865)	Immutep S.A.S.	2024-07-17
Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy (NCT05747794)	Immutep S.A.S.	2023-05-22
Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC (NCT04811027)	Immutep S.A.S.	2021-08-27
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (NCT03625323)	Immutep S.A.S.	2019-02-21

Every clearance here is in the API, with alerts when new ones post.